POLSKI  ENGLISH

Etyka badań medycznych

Marcin Waligóra, Sprawiedliwość, efektywność i metodologia w badaniach klinicznych

  1. Macklin R. Double standards in medical research in developing countries: Cambridge University Press; 2004.

  2. Piasecki J. Sprawiedliwość w międzynarodowych badaniach biomedycznych. w: Różyńska J, Waligora M, (red.), Badania naukowe z udziałem ludzi w biomedycynie. Standardy międzynarodowe. Warszawa: Wolters Kluwer Polska 2012.

  3. Harris J, Holm S. Should we presume moral turpitude in our children? - Small children and consent to medical research. Theor Med Bioeth. 2003;24(2):121-9.

  4. Harris J. Scientific research is a moral duty. J Med Ethics. 2005;31(4):242-8.

  5. Chan S, Harris J. Free riders and pious sons-why science research remains obligatory. Bioethics. 2009;23(3):161-71.

  6. Shapshay S, Pimple KD. Participation in biomedical research is an imperfect moral duty: a response to John Harris. J Med Ethics. 2007;33(7):414-7.

  7. Stjernschantz Forsberg J, Hansson MG, Eriksson S. Why participating in (certain) scientific research is a moral duty. J Med Ethics. 2014;40(5):325-8.

  8. Brassington I. John Harris' argument for a duty to research. Bioethics. 2007;21(3):160

  9. Brassington I. Defending the duty to research? Bioethics. 2011;25(1):21-6.

  10. Doll R. Controlled trials: the 1948 watershed. BMJ (Clinical research ed). 1998;317(7167):1217-20.

  11. Peirce CS JJ. On Small Differences in Sensation. Memoirs of the National Academy of Sciences 1885;3:73-83.

  12. Meldrum ML. A brief history of the randomized controlled trial. From oranges and lemons to the gold standard. Hematology/oncology clinics of North America. 2000;14(4):745-60.

  13. Hill AB. Principles of medicial statistics. London: The Lancet Ltd.; 1939.

  14. Yoshioka A. Use of randomisation in the Medical Research Council's clinical trial of streptomycin in pulmonary tuberculosis in the 1940s. BMJ (Clinical research ed). 1998;317(7167):1220-3.

  15. Feldman WH Hinshaw HC. Effects of streptomycin on experimental tuberculosis in guinea pigs: a preliminary report. Am RevTuberc. 1947;52:269-98.

  16. Hill B. Medical ethics and controlled trials. British Medical Journal. 1963;2.

  17. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ (Clinical research ed). 1996;312(7023):71-2.

  18. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed). 2008;336(7650):924-6.

  19. Holger Schünemann JB, Gordon Guyatt, Andrew Oxman (eds). GRADE Handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach 2009.

  20. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report, (1979).

  21. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Raport belmoncki. w: Galewicz W. (red.) Antologia bioetyki, t 3, Badania z udziałem ludzi. Kraków: Universitas 2011.

  22. The World Medical Association, Declaration of Helsinki, (1964).

  23. Levine RJ. The need to revise the Declaration of Helsinki. The New England Journal of Medicine. 1999;341(7):531-4.

  24. Declaration of Helsinki-Ethical Principles for Research Involving Human Subjects, (2013).

  25. Waligóra M. Etyka lekarza a etyka badacza, w: Różyńska J, Waligora M, (red.) Badania naukowe z udziałem ludzi w biomedycynie Standardy międzynarodowe. Warszawa: Wolters Kluwer Polska 2012.

  26. Freedman CB. Equipoise and the Ethics of Clinical Research. 1987;317(3).

  27. Grankvist H, Kimmelman J. How do researchers decide early clinical trials? Medicine, Health Care and Philosophy. 2016.

  28. Karlawish JH, Lantos J. Community equipoise and the architecture of clinical research. Cambridge Quarterly of Healthcare Ethics. 1997;6(4):385-96.

  29. Miller FG, Brody H. A critique of clinical equipoise. Therapeutic misconception in the ethics of clinical trials. The Hastings Center Report. 2003;33(3):19-28.

  30. Buchanan D, Miller FG. Principles of early stopping of randomized trials for efficacy: a critique of equipoise and an alternative nonexploitation ethical framework. Kennedy Institute of Ethics Journal. 2005;15(2):161-78.

  31. Miller FG. Equipoise and the ethics of clinical research revisited. The American Journal of Bioethics 2006;6(4):59-61;.

  32. Miller FG, Brody H. Clinical equipoise and the incoherence of research ethics. The Journal of Medicine and Philosophy. 2007;32(2):151-65.

  33. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. The New England Journal of Medicine. 2011;364(5):476-80.

  34. Miller FG. Dispensing with equipoise. The American Journal of the Medical Sciences. 2011;342(4):276-81.

  35. Veatch RM. The irrelevance of equipoise. The Journal of Medicine and Philosophy. 2007;32(2):167-83.

  36. Jansen LA. A closer look at the bad deal trial: beyond clinical equipoise. The Hastings Center Report. 2005;35(5):29-36.

  37. Gifford F. So-called "clinical equipoise" and the argument from design. The Journal of Medicine and Philosophy. 2007;32(2):135-50.

  38. Veatch RM. Indifference of subjects: an alternative to equipoise in randomized clinical trials. SocialPhilosophy & Policy. 2002;19(2):295-323.

  39. Chiong W. The real problem with equipoise. The American Journal of Bioethics 2006;6(4):37-47.

  40. Chiong W. Właściwy, słaby punkt teorii równowagi. w: Galewicz W. (red.) Badania z udziałem ludzi, Antologia Bioetyki, t3, Universitas: Krakow 2011.

  41. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology. 2011;64(4):401-6.

  42. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). Journal of Clinical Epidemiology. 2011;64(4):407-15.

  43. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA : The Journal of the American Medical Association. 2000;283(20):2701-11.

  44. Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, et al. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ (Clinical research ed). 2005;331(7528):1295.

  45. Djulbegovic B. Articulating and responding to uncertainties in clinical research. The Journal of Medicine and Philosophy. 2007;32(2):79-98.

  46. Djulbegovic B. Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research. Curr Oncol Rep. 2001;3(5):389-95.

  47. Zapol WM, Snider MT, Hill JD, Fallat RJ, Bartlett RH, Edmunds LH, et al. Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 1979;242(20):2193-6.

  48. Truog RD. Randomized controlled trials: lessons from ECMO. Clinical research. 1992;40(3):519-27.

  49. Adam Grzybowski, Ewa Urbańska, Roman Przybylski, Janusz H. Skalski. Pozaustrojowe utlenowanie krwi (ECMO). In: J.H. Skalski, Z. Religa (red.) Kardiochirurgia dziecięca, Katowice 2003.

  50. Bartlett RH, Gazzaniga AB, Huxtable RF, Schippers HC, O'Connor MJ, Jefferies MR. Extracorporeal circulation (ECMO) in neonatal respiratory failure. The Journal of Thoracic and Cardiovascular Surgery. 1977;74(6):826-33.

  51. Zelen M. Play the Winner Rule and the Controlled Clinical Trial. Journal of the American Statistical Association. 1969;64(325):131-46.

  52. Bartlett RH, Roloff DW, Cornell RG, Andrews AF, Dillon PW, Zwischenberger JB. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics. 1985;76(4):479-87.

  53. Rosenberger WF. Randomized play-the-winner clinical trials: review and recommendations. Controlled Clinical Trials. 1999;20(4):328-42.

  54. O'Rourke PP, Crone RK, Vacanti JP, Ware JH, Lillehei CW, Parad RB, et al. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study. Pediatrics. 1989;84(6):957-63.

  55. Zelen M. A new design for randomized clinical trials. NEJM. 1979;300(22):1242-5.

  56. Bennett CC, Johnson A, Field DJ, Elbourne D. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. Lancet. 2001;357(9262):1094-6.

  57. Mike V, Krauss AN, Ross GS. Neonatal extracorporeal membrane oxygenation (ECMO): clinical trials and the ethics of evidence. J Med Ethics. 1993;19(4):212-8.

  58. Lantos JD, Frader J. Extracorporeal membrane oxygenation and the ethics of clinical research in pediatrics. NEJM. 1990;323(6):409-13.

  59. Saxman SB. Ethical considerations for outcome-adaptive trial designs: a clinical researcher's perspective. Bioethics. 2015;29(2):59-65.

  60. Hey SP, Kimmelman J. Are outcome-adaptive allocation trials ethical? Clinical Trials . 2015;12(2):102-6.

  61. Lee JJ, Chen N, Yin G. Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clinical Cancer Research 2012;18(17):4498-507.

  62. Korn EL, Freidlin B. Commentary on Hey and Kimmelman. Clinical Trials 2015;12(2):122-4.

  63. Kim ES, Herbst RS, Wistuba, II, Lee JJ, Blumenschein GR, Jr., Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery. 2011;1(1):44-53.

  64. Lee JJ. Commentary on Hey and Kimmelman. Clinical Trials2015;12(2):110-2.